UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transitio ...

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q4 2022 Earnings Conference Call February 22, 2023 4:00 PM ET Company Participants Simon Latimer - Head, IR Todd Davis - CEO Tavo Espinoza - CFO Matthew Korenberg - President and Chief Operating Officer Conference Call Participants Joseph Pantginis - HC Wainwright Larry Solow - CJS Securities Matthew Hewitt - Craig-Hallum Capital Group Operator Good evening. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone ...

November 2022 Nasdaq: LGND Ligand Corporate Presentation SAFE HARBOR STATEMENT The following presentation contains forward-looking statements by Ligand and its partners that involve risks and uncertainties and reflect Ligand's and it's partners' judgment as of the date of this presentation. Words such as "plans," "believes," "expects," "projects," "could," "anticipates," and "will," and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, withou ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended September 30, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transitio ...

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO Matthew Korenberg - President & CFO Octavio Espinoza - CFO Conference Call Participants Joseph Pantginis - HC Wainwright Larry Solow - CJS Securities Matthew Hewitt - Craig-Hallum Capital Group Scott Henry - ROTH Capital Operator Good afternoon. My name is Vinesin, and I will be your conference actor today. At this time, I would like to welc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended June 30, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Per ...

Ligand Pharmaceuticals, Inc. (NASDAQ:LGND) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Simon Latimer - Head, IR John Higgins - CEO & Executive Director Matthew Korenberg - EVP, Finance & CFO Matthew Foehr - President & COO Conference Call Participants Peter Lukas - CJS Securities Matthew Hewitt - Craig-Hallum Operator Welcome to the Ligand Pharmaceuticals Second Quarter Earnings Conference Call. My name is Vanessa, and I will be your operator for today's call. [Operator I ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________________________________________________ FORM 10-Q ________________________________________________________________________________________ ☒ Quarterly Report Pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the quarterly period ended March 31, 2022 or ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the Transition Pe ...

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Simon Latimer - Head of Investor Relations John Higgins - CEO Matt Foehr - COO Matt Korenberg - CFO Conference Call Participants Larry Solow - CJS Securities Matt Hewitt - Craig Hallum Capital Operator Good day, everyone. And welcome to the Ligand Pharmaceuticals First Quarter '22 Earnings Call. At this time, all participants are in a listen-only mode [Operator Instructions]. Please ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________________________________________________________________________________ FORM 10-K _____________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 OR☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition ...